SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Stroke
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (54)3/14/2006 9:27:04 AM
From: dr.praveen   of 70
 
Hi Nigel,

The main aim of the chant trial is safety and tolerability. The drug can be given in the first golden hour and the paramedics can't use the imaging tech to distinguish it in the first hour. So i think this is a better study in that respect to give the drug immaterial of whether it is ischaemic or H'agic. Getting the drug in within the first golden hour of stroke is a total diff issue.

What puzzles me more is that it didn't fare well in the NIHSS scale which is more widely adopted. MRS scale looks very vague to me.

However I think due to the increased trial no, it may show marginal efficacy in Saint II trial and get approved with FDA due to low threshold.

Regards,
Praveen
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News